N1VO34 Stock Price and Chart — BMFBOVESPA:N1VO34

Overview

Financials News Ideas Discussions Technicals Seasonals Bonds

Key facts today

Novo Nordisk (NOVO_B) shares fell 47% in the past year, now at 450.20 kroner, due to tariff concerns, poor trial results, and slow prescription growth from production issues and generic competition.

Novo Nordisk (NOVO_B) is set to present weight-loss data at the upcoming American Diabetes Association meeting in June, marking a significant event for the company's pipeline.

Hims & Hers Health noted a shift of subscribers from Novo Nordisk's semaglutide to other options, expected to cause a one-time revenue decline in Q2.

Analyze the impact Analyze the impact

About NOVO NORDISK B A/S

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.